Agenus (AGEN)
(Delayed Data from NSDQ)
$4.68 USD
+0.02 (0.43%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $4.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.68 USD
+0.02 (0.43%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $4.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Zacks News
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.
Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
by Zacks Equity Research
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the company's third-quarter results.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) top line is expected to be driven by newly launched Apoquel, Simparica and Cytopoint. The approvals of Clavamox and Nexvet are expected to boost sales further.
Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?
by Zacks Equity Research
Teva's (TEVA) generic segment may continue to see weakness due to significant competitive and pricing pressure in the U.S. generics industry, which will continue to hurt the top line.
What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?
by Zacks Equity Research
Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.
What's in the Offing for Intercept (ICPT) in Q3 Earnings?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.
Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View
by Zacks Equity Research
Alkermes' (ALKS) earnings beat estimates but sales lagged the same in the third quarter of 2017.
Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised
by Zacks Equity Research
Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.
Is a Beat in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to report third-quarter 2017 on Oct 26.
Agenus (AGEN) Remains Focused on Drug Development Programs
by Zacks Equity Research
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
Why Is Agenus (AGEN) Down 11.8% Since the Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.
Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
by Zacks Equity Research
Agenus reported narrower-than-expected loss in the second quarter of 2017 but revenues missed expectations.
Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in Japan, which drove the company's top line. The company is also working on expanding its pipeline and Amitizia's label.
Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 6% on the day after the company delivered yet another quarter of greater than 100% top-line growth.
What's in Store for Endocyte (ECYT) this Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.
New Strong Buy Stocks for July 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
What to Expect from International Paper (IP) in Q2 Earnings?
by Zacks Equity Research
Fluctuations in actual equity market returns, changes in general interest rates are likely to hurt International Paper (IP) in Q2 earnings.
S&P Global (SPGI) to Post Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
S&P Global's (SPGI) strategic portfolio restructuring and focus on core business are expected to have a positive impact on the company's second-quarter results.
VASCO (VDSI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Vasco's (VDSI) focus on generating high operating margins, backed by continuous investments and a shift in the product mix with higher gross-margin products, is likely to boost its Q2 earnings.
Is a Beat in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) will focus on the development of all its pipeline drugs as currently there are no marketed drug in its portfolio.
What to Expect from Keryx (KERX) this Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia (IDA) indication.
Is a Beat in Store for Alexion (ALXN) this Earnings Season?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.
uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher
by Zacks Equity Research
uniQure N.V. (QURE) was a big mover last session, as the company saw its shares rise a little above 9% on the day.
New Strong Buy Stocks for July 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday